- Prostate cancer
Dr Chris Parker qualified in medicine from Oxford University in 1989. He trained in oncology at The Royal Marsden and gained his FRCR in 1996. After research fellowships, he was appointed Senior Lecturer and Honorary Consultant in Clinical Oncology and Prostate Cancer Translational research at The Institute of Cancer Research and The Royal Marsden in 2001.
His clinical practice concerns the management of prostate cancer. Particular interests include active surveillance of low-risk disease, the role of post-operative adjuvant therapy, and of bone-targeted therapy for advanced disease. He chairs the National Cancer Research Institute Prostate Clinical Studies Group and is a member of the Department of Health Prostate Cancer Advisory Group. He has published over 200 articles on prostate cancer.